Recursion Provides Business Updates and Reports Second Quart

Actively enrolling participants in our Phase 2/3 clinical trial for the potential treatment of progressive NF2-mutated meningiomas On track to initiate our...

Related Keywords

Montreal , Quebec , Canada , Salt Lake City , Utah , United States , Toronto , Ontario , Chris Gibson , Development Expenses , Genentech , Recursion Pharmaceuticals Inc , European Commission , Drug Administration , European Commission Orphan Drug , Children Tumor Foundation Nf Conference , Recursion Fast Track , Recursion Orphan Drug Designation , Tumor Foundation , Therapeutic Data Commons , Administrative Expenses , San Francisco Bay , Consolidated Statements , Consolidated Balance Sheets ,